INTRODUCTION:
The goal of this proposal is to therapeutically reverse the damaging effects of radiotherapy on bone formation and healing to enable non-vascularized grafting in irradiated bone. Utilizing a rodent model of mandibular bone grafting, we quantified metrics of diminished graft take and bone healing in response to radiation treatment. Subsequently, we utilized implantable deferoxamine (DFO)-an angiogenic stimulant, to reverse these radiation-induced detriments. We hypothesized that the addition of our proposed therapy, would evidence quantifiable degrees of remediation on the process of tissue regeneration, graft incorporation and bone healing.
METHODS:
Male Lewis rats received a human equivalent dose of radiotherapy (7Gy/d x 5d) to left hemi-mandibles. After recovery, a circular trephine burr (6mm) was utilized to create a critical size defect just posterior to the third molar, and a bone graft was harvested from the right hemimandible of the same animal and secured with a custom PLA resorbable plate. Three groups (n=8/group) of animals were investigated: Control, (irradiated) XRT and irradiated + implantable deferoxamine (DFO). Mandibles were imaged at 14, 40 and 60 days with in vivo µCT, and a 60-day healing period was allowed prior to further outcomes testing. Bony union was judged clinically by 3 blinded reviewers on a scale from 0 to 4, representing the approximate percentage of robust union formation along the circular graftrecipient site interface (e.g. 1=25%, 4=100%). Statistical comparisons were conducted with ANOVA (p<0.05).
RESULTS:
We observed a significant diminution of bone graft healing after radiotherapy. At 60 days, the bone volume fraction (BVF) of the XRT group decreased by 20% (p=0.001), and exhibited lower bony union scores when compared to control (p=0.005). With the addition of DFO, these findings were largely remediated. At 60 days, the BVF improved upon the XRT BVF by 12% (p=0.025), and was not different than control (p=0.282). In addition, the bony union scores of the implanted DFO group significantly improved from XRT levels (p=0.05), and were not different than control (p=0.200).
CONCLUSION: Implantable DFO strongly remediates the effects of radiation on non-vascularized bone graft incorporation and healing as measured by micro-densitometry and bony union analysis. These observations are promising with regards to the potential utility of this therapy to enhance bone graft incorporation in the irradiated mandible for head and neck cancer survivors. 
Differential Osteogenic Signaling

Non-Mineralized and Mineralized Collagen Scaffolds Induce Differential Osteogenic Signaling Pathways in Human Mesenchymal Stem Cells
INTRODUCTION:
The instructive capabilities of extracellular matrix components in progenitor cell differentiation have recently generated significant interest in the development of bioinspired materials for regenerative applications. Previously, we described a correlation between the osteogenic capabilities of nanoparticulate mineralized collagen glycosaminoglycan scaffolds (MC-GAG) and an autogenous activation of Smad1/5 in the canonical bone morphogenetic protein receptor (BMPR) pathway with a diminished ERK1/2 activation when compared to non-mineralized scaffolds (Col-GAG) . In this work, we utilize a canonical BMPR inhibitor, DMH1, and an inhibitor of the PSTM 2017 Abstract Supplement
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MEK/ERK cascade, PD98059, to characterize the necessity of each pathway for osteogenesis.
METHODS: hMSCs were cultured in osteogenic media on Col-GAG or MC-GAG scaffolds. Scaffolds were untreated or treated with the DMH1 or PD98059 at 50 mM for 4 days, 14 days, 24 days, 4 weeks, and 8 weeks. Gene and protein expression were measured using quantitative RT-PCR and western blot analysis. Scaffolds were subjected to histochemical and micro-computed tomographic analyses.
RESULTS:
Inhibition of the BMPR signaling pathway inhibited Runx2 and BSPII gene expression of primary human mesenchymal stem cells (hMSCs) on MC-GAG. In contrast, inhibition of the MEK/ERK axis downregulated BSPII expression on Col-GAG independent of Runx2 expression. While inhibition of the BMPR signaling pathway resulted in decreased mineralization on both Col-GAG and MC-GAG, inhibition of the MEK/ERK axis only affected mineralization on Col-GAG. When the mechanistic detais were evaluated in greater detail, inhibition of the BMPR pathway reduced both Smad1/5 phosphorylation and Runx2 protein expression on both MC-GAG and Col-GAG. Inhibition of the MEK/ERK axis downregulated phosphorylation of ERK1/2 and JNK1/2 without affecting Smad1/5 phosphorylation or Runx2 expression.
CONCLUSION:
Interactions between hMSCs and collagen-based materials result in mechanistic differences in osteogenesis. Activation of the canonical BMPR signaling is required for osteogenic differentiation and mineralization of hMSCs on Col-GAG or MC-GAG. The MEK/ERK cascade, intimately tied to JNK activation, is necessary for Runx2-independent osteogenesis on Col-GAG, while completely dispensable in osteogenesis on MC-GAG. 
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